Zacks Investment Research upgraded shares of MEDASSETS INC (MDAS) from UNDERPERFORM to NEUTRAL on January 06, 2014, with a target price of $20.50.
MedAssets' is a margin and cash flow improvement company providing innovative solutions for healthcare providers. MedAssets exists to help hospitals find cash from existing operations and to improve margins so healthcare providers can continue to serve their communities. MedAssets addresses cost and revenue issues simultaneously with proprietary technology that increases visibility and allows hospitals to realistically assess profitability.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MEDASSETS INC (MDAS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment